Omadacycline Oral Tablet [Nuzyra] ( DrugBank: Omadacycline )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 299 | Cystic fibrosis | 1 |
299. Cystic fibrosis
Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04460586 (ClinicalTrials.gov) | July 1, 2021 | 1/7/2020 | Pharmacokinetics of Omadacycline in Cystic Fibrosis | Pharmacokinetics of Omadacycline in Patients With Cystic Fibrosis | Cystic Fibrosis | Drug: Omadacycline Injection [Nuzyra];Drug: Omadacycline Oral Tablet [Nuzyra] | Paul Beringer | Paratek Pharmaceuticals Inc | Recruiting | 18 Years | N/A | All | 12 | Phase 4 | United States |